Market Place
Sourcing Support
Aligos Therapeutics Announces FDA Clearance For ALG-000184
22 Oct 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Acceptance Of Abstracts At The Liver Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Aligos Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Oct 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Appoints David Perry as VP of Business Development
01 Oct 2024 //
GLOBENEWSWIRE
Aligos Therapeutics to Present at Investor Conferences in October
30 Sep 2024 //
GLOBENEWSWIRE
Aligos Appoints Hardean Achneck as Chief Medical Officer
24 Sep 2024 //
GLOBENEWSWIRE
Aligos MASH Treatment Trial Succeeds, Despite Unusual Placebo Group Trend
20 Sep 2024 //
ENDPTS
Aligos Therapeutics Announces Positive Results For ALG-055009
19 Sep 2024 //
GLOBENEWSWIRE
Aligos MASH prospect slashes liver fat in phase 2
19 Sep 2024 //
FIERCE BIOTECH
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Rule
13 Sep 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Announces Reverse Stock Split
15 Aug 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Strengthens Board with Two New Independent Directors
08 Aug 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Reports Q2 2024 Results And Business Progress
06 Aug 2024 //
GLOBENEWSWIRE
Aligos Therapeutics To Announce Q2 2024 Results On August 6
30 Jul 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Announces Clinical Collaboration With Xiamen Amoytop
22 Jul 2024 //
GLOBENEWSWIRE
Aligos Therapeutics To Host KOL Event On ALG-000184 CHB Data
10 Jul 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
05 Jun 2024 //
GLOBENEWSWIRE
Aligos Abstracts Accepted For Presentation At EASL 2024
22 May 2024 //
GLOBENEWSWIRE
Aligos Completes ALG-055009 MASH Phase 2a Enrollment
21 May 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Q1 2024 Results and Business Progress
06 May 2024 //
GLOBENEWSWIRE
Aligos To Announce Q1 2024 Financials On May 7
30 Apr 2024 //
GLOBENEWSWIRE
Aligos Mourns MASH Leader Stephen A. Harrison, MD
25 Apr 2024 //
GLOBENEWSWIRE
Aligos Shows ALG-097558 Positive Phase 1 Data at ESCMID
25 Apr 2024 //
GLOBENEWSWIRE
Aligos to Participate in the Piper Sandler Spring Biopharma Symposium 2024
09 Apr 2024 //
GLOBENEWSWIRE
Aligos Announces First Dosed in the Ph 2a of ALG-055009 in MASH Subjects
03 Apr 2024 //
GLOBENEWSWIRE
Aligos Presents Positive Clinical Data at APASL 2024 from ALG-055009
27 Mar 2024 //
GLOBENEWSWIRE
Aligos Announces the Initiation of the Phase 2a of ALG-055009 in MASH Subjects
18 Mar 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
Aligos to Announce 4th Quarter 2023 Financial Results on March 12, 2024
05 Mar 2024 //
GLOBENEWSWIRE
Aligos To Participate in the Leerink Partners Global Biopharma Conference 2024
26 Feb 2024 //
GLOBENEWSWIRE
Aligos to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009
20 Feb 2024 //
GLOBENEWSWIRE
Aligos Therapeutics Strengthens Finance Leadership Team with Two Appointments
13 Feb 2024 //
GLOBENEWSWIRE
Aligos Presents Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184)
07 Dec 2023 //
GLOBENEWSWIRE
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
Hepatitis B drug developers chart slow progress, just like hep C
14 Nov 2023 //
FIERCE BIOTECH
Aligos Therapeutics Presents Data at the AASLD Liver Meeting 2023
13 Nov 2023 //
GLOBENEWSWIRE
Aligos Presents Positive Data at the AASLD Liver Meeting 2023 of ALG-000184
10 Nov 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Present Multiple Posters at AASLD™s The Liver Meeting
07 Nov 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1
03 Nov 2023 //
GLOBENEWSWIRE
Aligos Reports Recent Business Progress and Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
26 Oct 2023 //
GLOBENEWSWIRE
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184
25 Oct 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Announces $92 Million Private Placement Financing
23 Oct 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract
03 Oct 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
21 Sep 2023 //
GLOBENEWSWIRE
Aligos culls another hep B asset over inconclusive efficacy data
04 Aug 2023 //
FIERCE BIOTECH
Aligos Therapeutics Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
27 Jul 2023 //
GLOBENEWSWIRE
Aligos Announces the Selection of Stephen Harrison as Principal Investigator of Ph2a Study for ALG-055009
19 Jul 2023 //
GLOBENEWSWIRE
Aligos Presents Data from its Liver Disease Programs at the EA for (EASL)
21 Jun 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Present Data on its Liver Disease Programs
07 Jun 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
24 May 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Collaborate with Xiamen Amoytop Biotech
15 May 2023 //
INVESTING
Aligos Announces Research Agreement with Xiamen Amoytop
12 May 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Reports Recent Business Progress and 1Q 2023 FYR
04 May 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
27 Apr 2023 //
GLOBENEWSWIRE
Aligos to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs
11 Apr 2023 //
GLOBENEWSWIRE
Aligos Presents Data from NASH Program at the 2023 Paris Hepatology Conference
29 Mar 2023 //
GLOBENEWSWIRE
Aligos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
28 Feb 2023 //
GLOBENEWSWIRE
